ReviewMedicine2026
Strategies and innovations in hypertension management for sickle cell patients: A narrative review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) remains a challenging hematologic disorder, characterized by chronic hemolysis, vaso-occlusive events, and multi-organ complications. Hypertension, a prevalent comorbidity in SCD, poses significant clinical implications, exacerbating the complexities of disease management and impacting patient outcomes. Understanding the intricate interplay between SCD and hypertension is pivotal. Mechanistic insights uncover a landscape characterized by chronic hemolysis, endothelial dysfunction, altered nitric oxide bioavailability, and increased oxidative stress, contributing to elevated blood pressure and heightened cardiovascular risks in individuals with SCD. The diagnostic challenges inherent in identifying and monitoring hypertension in SCD patients necessitate novel approaches. Current treatment paradigms encompass a spectrum of lifestyle modifications, pharmacological interventions, and multidisciplinary care models. However, the limitations and complexities inherent in managing hypertension in SCD call for innovative strategies. Tailored approaches, personalized treatments, and emerging therapeutic avenues geared explicitly toward SCD patients mark a shift toward more effective management. Advancements in technology, including wearable devices and remote monitoring systems, present opportunities to revolutionize blood pressure monitoring, enhancing patient engagement and compliance while providing more accurate and frequent measurements. Moreover, the review underscores the importance of integrated care models and multidisciplinary collaborations. Collaborative frameworks involving hematologists, cardiologists, nephrologists, and primary care physicians are integral in optimizing hypertension management and addressing the specific needs of individuals with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.